Industry Requests Decreased Filing Burden For Improved Analytical Methods
FDA should consider a decreased filing burden for improved post-approval analytical methods, industry participants contended at a recent FDA/American Association of Pharmaceutical Scientists workshop on packaging and analytical methods post-approval changes.
You may also be interested in...
FDA and the pharmaceutical industry should draft a list of "CDER-approved" container closure components as a supplement to the upcoming packaging post-approval changes guidance, participants recommended at an FDA/American Association of Pharmaceutical Scientists workshop on packaging and analytical method post-approval changes.
FDA's proposed rule "Supplements and Other Changes to an Approved Application" and its accompanying guidance should be abandoned, the Pharmaceutical Research & Manufacturers of America asserted in Aug. 27 comments to the agency.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011